Every material Form 8-K Bioventus Inc. has filed with the SEC since May 21, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Bioventus reported third-quarter 2026 revenue of $142.4 million, up 3%, and net income attributable to the company of $6.0 million, up from $3.2 million a year earlier. The company reaffirmed its 2026 adjusted EPS guidance of $0.75 to $0.79 per diluted share and updated net sales guidance to $590 million to $595 million, while continuing to review potential strategic alternatives that followed an unsolicited acquisition proposal.
Q3 2026 revenue of $142.4 million rose 3%, led by Pain Treatments, which grew 6.2% to $71.3 million
GAAP diluted EPS was $0.08 versus $0.05 a year earlier; non-GAAP diluted EPS was $0.17 versus $0.15
2026 guidance: adjusted EPS of $0.75 to $0.79 reaffirmed; net sales of $590 million to $595 million
Company continues to review potential strategic alternatives; cash from operations was $20.7 million in Q3
Bioventus reported second-quarter 2026 revenue of $153.2 million, up 4%, and GAAP diluted earnings of $0.47 per share versus $0.11 a year earlier. The company reaffirmed its full-year 2026 guidance and said its board has begun a review of strategic alternatives, including a possible sale, after receiving an unsolicited acquisition proposal. The filing sets no timetable for the review and says there is no assurance it will lead to a transaction.
Q2 net sales were $153.2 million, up 3.8%, with Pain Treatments up 11.5% to $81.7 million
GAAP diluted EPS was $0.47 versus $0.11, helped by removal of a $24.6 million deferred tax valuation allowance; non-GAAP EPS was $0.22 versus $0.21
2026 guidance reaffirmed: net sales $600 million to $610 million, adjusted EPS $0.75 to $0.79, cash from operations $84 million to $89 million
Independent board committee, advised by Evercore and Latham & Watkins, is evaluating a sale or continued standalone plan; no timetable set
Bioventus disclosed that the FDA issued a final order on April 16, 2026 reclassifying non-invasive bone growth stimulators, including its Exogen Ultrasound Bone Healing System, from Class III to Class II devices. CMS also updated billing requirements and the Medicare fee schedule for these devices for dates of service on or after May 18, 2026, and the company reiterated its 2026 financial guidance, though it said further CMS changes could require a revised outlook.
FDA final order dated April 16, 2026 reclassified bone growth stimulators from Class III to Class II
CMS updated billing requirements and Medicare fee schedule under HCPCS codes E0747, E0748, and E0760 for dates of service on or after May 18, 2026
Bioventus does not presently expect reimbursement rate changes to have a material impact on 2026 results and reiterated its 2026 guidance
Future CMS changes to Exogen Medicare reimbursement rates could require a revised financial outlook
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Bioventus Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →